| March 20, 2008
Treanda Treats Rare Cancer
THURSDAY, March 20 (HealthDay News) — The Cephalon drug Treanda (bendamustine hydrochloride) has been approved by the U.S. Food and Drug Administration to treat chronic lymphocytic leukemia, a rare cancer that affects the blood and bone marrow.
CLL is expected to strike some 15,000 people in the United States this year, according to American Cancer Society estimates provided by the drugmaker.
In a trial of 301 patients that compared Treanda to an already approved chemotherapy drug, Treanda recipients had better response rates and longer progression-free survival, Cephalon said in a statement.
Treanda, expected to hit the U.S. market in April, works by damaging the DNA in cancer cells, causing these cells to die. Cephalon said the treatment was granted orphan drug status by the FDA, which offers companies exclusive marketing rights in return for drugs developed for rare diseases.
SOURCE: www.medicinenet.com
Comment:
Chronic lymphocytic leukemia is a type of cancer in which the
bone marrow makes too many lymphocytes (a type of white blood cell). It
is a disease that occurs in older adults and usually worsens slowly. The
disease progression can sometimes be so slow that immediate treatment is
also not indicated. Due to this background, this drug is granted special
“orphan drug” status with exclusive marketing rights and accelerated
approval because it is developed for a rare disease.
Dr. Rath has conducted groundbreaking research using the innovative nutrient synergy method in various chronic diseases and cancer. So far, the scientists at the Dr. Rath Research Institute have tested 30 different types of cancer lines and have proven the safety and effectiveness of this novel method. Please read more about Dr. Rath's groundbreaking research in cancer on www.drrathresearch.org.
|
|
